Oral Proteins And Peptides Market Growth, Recent Trends, Key Players And Forecast To 2033

The Business Research Company recently released a comprehensive report on the Global Oral Proteins And Peptides Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp

According to The Business Research Company's, The oral proteins and peptides market size has grown exponentially in recent years. It will grow from $1.04 billion in 2023 to $1.27 billion in 2024 at a compound annual growth rate (CAGR) of 22.1%. The growth in the historic period can be attributed to the rising prevalence of chronic diseases, increasing investments in biotechnology for the development of oral protein-based treatments, growing consumer preference for non-invasive treatments, increasing biopharmaceutical industry, and rising focus on personalized medicine.

The oral proteins and peptides market size is expected to see exponential growth in the next few years. It will grow to $2.86 billion in 2028 at a compound annual growth rate (CAGR) of 22.4%. The growth in the forecast period can be attributed to increasing focus on patient-centric drugs, increasing prevalence of the geriatric population, rising healthcare expenditure, growing need for diagnostics in cancer, and rising preference for oral drugs. Major trends in the forecast period include development of novel oral peptides with enhanced stability and efficacy, integration of artificial intelligence in drug discovery processes for oral formulations, advanced medical treatments, advancements in drug delivery technologies, and innovative oral insulin formulations.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report

Market Drivers and Trends:

The growing biopharmaceutical industry is expected to propel the growth of the oral proteins and peptides market going forward. The biopharmaceutical industry is a sector within the broader pharmaceutical industry that focuses on developing, producing, and commercializing drugs derived from biological sources. The growth of the biopharmaceutical industry is due to advancements in biotechnology, growing demand for personalized medicine, increasing prevalence of chronic diseases, and rising investment in research and development. Oral proteins and peptides in biopharmaceuticals offer potential for non-invasive delivery of therapeutics, enhancing patient compliance and reducing the need for injections. They can target specific diseases with improved stability and absorption in the digestive system. For instance, in June 2023, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based European trade association representing the pharmaceutical industry, the total bio-pharmaceutical production in Europe accounted for $384,200 million (€340,000 million) in 2022, an increase of approximately 4.95% from $366,267 million (€323,950 million) in 2021. Therefore, the growing biopharmaceutical industry is driving the growth of the oral proteins and peptides market.

Major companies operating in the oral proteins and peptides market are focusing on developing innovative products, such as Oral Semaglutide, to enhance patient adherence and comfort. Oral semaglutide is a groundbreaking medication that significantly advances oral proteins and peptides. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, traditionally administered via injection to treat type 2 diabetes and, more recently, obesity. For instance, in January 2022, Novo Nordisk India, an India-based healthcare company, launched the world's first oral semaglutide, marking a revolutionary advance in diabetes treatment. Semaglutide is a GLP-1 receptor analogue (GLP-1 RA) previously available only in injectable form, now offers a more convenient oral option for managing type 2 diabetes. This breakthrough not only transforms diabetes care but also sets the stage for future innovations in oral insulin formulations, potentially leading to more effective and patient-friendly treatment options.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Major Key Players of the Market:

Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

Oral Proteins And Peptides Market 2024 Key Insights:

• The oral proteins and peptides market size is expected to see exponential growth in the next few years. It will grow to $2.86 billion in 2028 at a compound annual growth rate (CAGR) of 22.4%.
• Growing Biopharmaceutical Industry
• Breakthrough Oral Insulin Technologies In Diabetes Care
• North America was the largest region in the oral proteins and peptides market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/customise?id=19629&type=smp

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (https://www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.